Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15214MR)

This product GTTS-WQ15214MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFSF13&TNFSF13B gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001198622.2; NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8741; 10673
UniProt ID Q2QBA2; Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15214MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5943MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CL-2C
GTTS-WQ12954MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PDL 192
GTTS-WQ15328MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ11152MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MDX-1333
GTTS-WQ14829MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SGN-75
GTTS-WQ12110MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-003
GTTS-WQ718MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA A-623
GTTS-WQ11489MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MetMAb
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW